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Abstract
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a
collection of health-related quality of life (HRQOL) questionnaires targeted to the management of
chronic illness. The measurement system, under development since 1987, began with the creation
of a generic CORE questionnaire called the Functional Assessment of Cancer Therapy-General
(FACT-G). The FACT-G (now in Version 4) is a 27-item compilation of general questions divided
into four primary QOL domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-
Being, and Functional Well-Being. It is appropriate for use with patients with any form of cancer,
and extensions of it have been used and validated in other chronic illness condition (e.g., HIV/AIDS;
multiple sclerosis; Parkinson's disease; rheumatoid arthritis), and in the general population. The
FACIT Measurement System now includes over 400 questions, some of which have been translated
into more than 45 languages. Assessment of any one patient is tailored so that the most-relevant
questions are asked and administration time for any one assessment is usually less than 15 minutes.
This is accomplished both by the use of specific subscales for relevant domains of HRQOL, or
computerized adaptive testing (CAT) of selected symptoms and functional areas. FACIT
questionnaires can be administered by self-report (paper or computer) or interview (face-to-face
or telephone). Available scoring, normative data and information on meaningful change now allow
one to interpret results in the context of a growing literature base.
Review
What is the FACIT Measurement System?
The FACIT Measurement System is a collection of health-
related quality of life (HRQOL) questionnaires targeted to
the management of chronic illness. "FACIT" (Functional
Assessment of Chronic Illness Therapy) was adopted as
the formal name of the measurement system in 1997 to
portray the expansion of the familiar "FACT" (Functional
Assessment of Cancer Therapy) questionnaires into other
chronic illnesses and conditions.
The measurement system, under development since 1987,
began with the creation of a generic CORE questionnaire
called the Functional Assessment of Cancer Therapy-Gen-
eral (FACT-G). The FACT-G (now in Version 4) is a 27-
item compilation of general questions divided into four
primary QOL domains: Physical Well-Being, Social/Fam-
ily Well-Being, Emotional Well-Being, and Functional
Well-Being. It is considered appropriate for use with
patients with any form of cancer, and has also been used
and validated in other chronic illness condition (e.g.,
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HIV/AIDS and multiple sclerosis) and in the general pop-
ulation (using a slightly modified version).
Validation of a core measure allowed for the evolution of
multiple disease, treatment, condition, and other targeted
questionnaires. FACIT scales are constructed to comple-
ment the FACT-G, addressing relevant disease-, treatment-
, or condition-related issues not already covered in the
general questionnaire. Each is intended to be as specific as
necessary to capture the clinically-relevant problems asso-
ciated with a given condition or symptom, yet general
enough to allow for comparison across diseases, and
extension, as appropriate, to other chronic medical condi-
tions. The latest version of the FACIT Measurement Sys-
tem, Version 4, was designed to enhance clarity and
precision of measurement without threatening its estab-
lished reliability and validity (from Version 3). Format-
ting simplification, item-reduction, and rewording
(standardizing items across scales) constitute the major
areas of change from version 3 to 4. To facilitate the clini-
cal utility of the FACIT system, new methods for computer
acquisition, scoring, and display of data will be available.
These additions and improvements will likely ease patient
burden, expedite data collection and scoring, and further
guide the clinician or researcher in meaningful
interpretation.
As of spring, 2003, there are over 40 different FACIT scales
and nine disease-specific symptom indices. FACIT scales
include 3 general, 14 disease-specific, 5 treatment-spe-
cific, 8 condition-specific, and 10 non-cancer specific
measures.
Why assess health-related quality of life with the FACIT 
Measurement System?
The FACIT Measurement System offers several benefits to
an investigator seeking to measure HRQOL in people with
cancer, HIV disease, multiple sclerosis, arthritis and other
conditions. First, item content was determined by com-
bined expert and patient input, ensuring that clinically
important issues relevant to patients are included. Second,
there are several hundred publications detailing its per-
formance, many of which are reports of formal validation
studies. Thus, there is a deep reference literature to which
one can compare results. A third advantage to FACIT is the
availability of normative and cross-illness comparative
scores to which one can relate results. Finally, a growing
body of research has illustrated clinically significant dif-
ferences and changes in scores in FACIT scales, aiding in
study sample size determination and interpretation of
study results.
How was the FACIT developed and validated?
Most FACIT measures have undergone a standard scale
development and validation methodology, which takes
place in four phases: item generation, item-reduction,
scale construction, and psychometric evaluation [1-22].
The scale development process involves considerable
input from patients and expert health care providers,
using a semi-structured interview designed to elicit per-
sonal experiences and educated opinions about how a dis-
ease, treatment, or condition may affect physical status,
emotional well-being, functional well-being, family /
social issues, sexuality/intimacy, work status, and future
orientation. This process yields an exhaustive list of candi-
date items, which then undergo a series of reviews and
reductions based on patient and expert ratings and item
quality. A finite set of targeted concerns are then derived.
Final candidate items are formatted with response choices
compatible with a 5-point Likert-type scale, and
appended to the FACT-G.
Newly constructed FACIT subscales then undergo an ini-
tial assessment of reliability and validity using a sample of
at least 50 patients. The validation design typically
involves patient completion of a baseline assessment, a
test-retest assessment 3–7 days later, and a third assess-
ment 2–3 months later to demonstrate sensitivity to
change over time. Relevant sociodemographic and treat-
ment data is also collected and a battery of other measures
administered at the baseline and 2–3 month retest to help
determine convergent and divergent validity. A compre-
hensive analysis of the data gathered (including item
response theory modeling when sample size allows)
yields useful psychometric information and establishes
initial reliability and validity of the scale.
Which language translations are available?
Equivalent foreign language versions of the FACIT ques-
tionnaires are now available in more than 45 different
languages (for some scales), permitting cross-cultural
comparisons of people from diverse backgrounds (see
http://www.facit.org for details). FACIT language transla-
tions include the following: Afrikaans, Arabic, Bulgarian,
Chinese-Simplified, Chinese-Traditional, Croation,
Czech, Danish, Dutch, English, Estonian, Farsi, Finnish,
French, Georgian, German, Greek, Hebrew, Hindi, Hun-
garian, Indonesian, Italian, Japanese, Korean, Latvian,
Lithuanian, Malay, Marathi, Norwegian, Pedi, Polish, Por-
tuguese, Romanian, Russian, Serbian, Slovak, Slovene,
Spanish, Swahili, Swedish, Tagalog, Tamil, Telugu, Thai,
Tswana, Turkish, Vietnamese, and Zulu.
The FACIT Translation Project team has developed a sci-
entific approach to translating patient reported outcomes
measures, which includes a rigorous forward-backward-
forward methodology, psychometric testing, and cogni-
tive interviewing. This process was developed to ensure
that the resulting measures are both conceptually equiva-
lent as well as cross-culturally valid, thus enabling dataHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/79
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pooling in multinational clinical trials that enroll patients
who speak various languages.
The FACIT Translation Project was initiated to fulfill a
need for valid and reliable HRQOL assessment instru-
ments in languages other than English as part of the FACIT
Measurement System. The translation methodology
developed for the FACIT project has proven to be success-
ful in adapting questionnaires into European, Asian and
African languages. The list of available languages has
grown, keeping pace with the globalization of medical
outcomes research.
Why are the FACIT questionnaires good instruments to 
consider using?
There are many questionnaires available to measure
HRQOL of people with chronic illnesses. The FACIT ques-
tionnaires are some of the more commonly used ques-
tionnaires in national and international research settings.
Selecting an appropriate outcome measure is often driven
by many considerations including the purpose of the
study, the patient-reported endpoint required to address
the study purpose, the content of the items in the ques-
tionnaire with regard to the study purpose, and the valid-
ity of the questionnaire. Although no single questionnaire
is right for all studies, the FACIT Measurement System
provides an array of generic and targeted measures with
multiple benefits regarding validity, ease of administra-
tion, global application, and interpretation.
• Approximately 50 different generic and targeted question-
naires and symptom indices
• Range of questionnaires allow for greater disease, treatment
or condition specificity
• Easy to complete (most in 5–10 minutes)
• Demonstrated reliability, validity and sensitivity to change
• Some questionnaires translated and pre-tested in over 45
languages
• Special consideration for spiritual well-being, palliative care,
and treatment satisfaction
• More social well-being coverage than most other commonly-
used instruments
• Written at the 4th Grade reading level (9–10 years old) or
below
• Demonstrated equivalence in mode of administration (inter-
view vs. self-administration)
• Validated for use with special populations such as with the
elderly and those living in rural areas
• Appropriate for use in patients with a variety of chronic health
conditions, and in the general population
• Multiple scoring options: subscale scores, total score, and a
Trial Outcome Index (TOI)
• Used by major cooperative clinical trial groups, international-
industry sponsored research, other government/military funded
research, and health practice self studies
• No charge for use of the English versions
What are the applications of the FACIT?
Current implementation of the FACIT questionnaires
range in use from Phase I, II, and III clinical trials and
other treatment evaluations, as an intervention tool in the
clinical management of symptoms (both physical and
psychological), and as an outcomes measure in health
practice studies.
What areas of health does it measure?
Four primary quality of life domains are covered in the
general measure: Physical Well-Being (PWB; 7-items),
Social/Family Well-Being (SWB; 7-items), Emotional
Well-Being (EWB; 6-items); and Functional Well-Being
(FWB; 7-items). Disease-, treatment-, and condition-spe-
cific scales, and the non-cancer specific scales (e.g., spirit-
ual well-being, treatment satisfaction) cover additional
physical, functional, social, emotional and/or treatment-
related concerns.
How long does it take to complete?
Respondent burden is typically minimal given that the
questionnaire is written at the 4th grade-reading level, and
is specifically formatted for ease of self-administration.
Average time to complete the 27-item FACT-G is 5–10
minutes, and even less for the stand-alone scales and
symptom indices. As a rule of thumb, it takes 2–3 minutes
to complete 10 questions, so administration length can be
estimated after one selects the subscales to be combined
in one's assessment plan. The option to complete the
questionnaire by interview decreases burden for patients
whose condition (e.g. fatigue; poor eyesight) or mood
preclude them from completing the questionnaire by self-
administration, but may increase completion time.
How is the FACIT administered?
The FACIT scales are designed for patient self-administra-
tion, either on paper or direct to computer. They can also
be administered using face-to-face or telephone interview.
Interview administration is appropriate with adequate
training of interviewers to minimize bias to patientHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/79
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responses. One of the aims of a large multicenter study of
cancer and HIV patients (N = 1615) was to test the psy-
chometric properties and statistical equivalence of the
English and Spanish language versions of the FACT sub-
scales across literacy level (low vs. high) and mode of
administration (self report vs. interview). Technical equiv-
alence across mode of administration was demonstrated
in the high literacy patients; there were few differences in
data quality or psychometric measurement properties of
the FACT-G. Technical equivalence between modes of
administration with the FACT permits unbiased assess-
ment of the impact of chronic illnesses and their treat-
ments on patients from diverse backgrounds [23].
We have additional data to support the appropriateness of
computer-administered versions of the questionnaire,
including a multimedia touchscreen program [24]. We are
currently developing other novel administration methods
such as computer-assisted telephony and web-based
administration. Across these modes of administration,
our preliminary data suggest that while there are small dif-
ferences in the way people respond based on mode of
administration, these alternate formats are essentially
equivalent.
How is the FACIT scored?
All FACIT scales are scored so that a high score is good. To
achieve this, we reverse response scores on negatively-
phrased questions, then sum item responses. In cases
where individual questions are skipped, scores are pro-
rated using the average of the other answers in the scale.
The total FACT-G score is obtained by summing individ-
ual subscale scores (PWB + EWB + SWB + FWB). Total
scores for the disease-, treatment-, and condition-specific
subscales are obtained by summing all subscale scores
(PWB + EWB + SWB + FWB + additional concerns sub-
scale). For these scales there is also the option to calculate
a Trial Outcome Index (TOI). The TOI can be computed
for any FACIT disease-, treatment-, or condition-specific
scale. It is the sum of the Physical Well-Being (PWB),
Functional Well-Being (FWB), and "additional concerns"
subscales. Our experience with this TOI endpoint is that it
is an efficient summary index of physical/functional out-
comes. It is therefore a common endpoint used in clinical
trials, because it is responsive to change in physical/func-
tional outcomes, sometimes more than a total (overall)
multidimensional aggregated score, which includes social
and emotional well-being. While social and emotional
well-being are very important to quality of life, they are
not as likely to change as quickly or dramatically over time
or in response to physical health interventions such as
pharmaceutical treatments in clinical trials.
When there are missing data, prorating subscale scores is
acceptable as long as more than 50% of the items were
answered (e.g., a minimum of 4 of 7 items, 4 of 6 items,
etc). The total (FACT-G) score is considered appropriate to
score as long as overall item response rate is greater than
80% (e.g., at least 22 of 27 FACT-G items completed).
Is there automated administration or scoring software?
Raw score scoring templates and computer scoring pro-
grams written for use with both SAS and SPSS statistical
software packages are available for all FACIT measures.
We are currently developing computer-administered pro-
grams for various FACIT questionnaires. Packages will
include a patient-friendly computer-administered ques-
tionnaire, with automatic scoring and the ability to plot
individual patient scores longitudinally on a reader-
friendly graph. Some programs may also offer plotted
graphs with patient and normative reference data. We
expect to have these programs available by the end of
2003. See http://www.facit.org for updates.
How are FACIT scores interpreted?
Higher scores for the scales and subscales indicate better
quality of life. Average FACT-G scores for a group of
patients can be compared to normative data to determine
the HRQOL of the patients relative to the general U.S.
population. These comparisons facilitate meaningful
interpretation of HRQOL in patient populations.
Normative data for the FACT-G and the 13-item fatigue
subscale have been collected on 1,075 men and women
drawn from the general U.S. population. The range of ages
in the sample was 18 to 91 years with a mean (s.d.) of 45.9
(16.6), 50.6% were female, 75.9% were white, and 87.8%
had at least a high school education. Means (s.d.) for
FACT-G and fatigue subscale scores were 80.1 (18.1) for
total FACT-G; 22.7 (5.4) for PWB; 19.1 (6.8) for SWB;
19.9 (4.8) for EWB; 18.5 (6.8) for FWB, and 40.1 (10.4)
for the fatigue subscale. Normative data have also been
established separately for males and females and for 10-
year age groups. For more information on U.S. population
norms for the FACT-G visit our website at http://
www.facit.org.
Are the FACIT questionnaires responsive to change? What 
is a meaningful change in a FACIT score?
The FACIT instruments have been shown to be responsive
to change in both clinical and observational studies. Con-
siderable work has been done in recent years to identify
minimally important differences (MIDs) for scores of
scales and subscales from several FACIT instruments. An
MID is the "smallest difference in score in the domain of
interest that patients perceive as important, either benefi-
cial or harmful, and that would lead the clinician to con-
sider a change in the patient's management" (p 377) [25].
MIDs were identified using both anchor- and distribu-
tion-based methods [26]. MID estimates may vary acrossHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/79
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patients and possibly across patient groups; thus, ranges
of MIDs were identified for some scales. As TOIs are fre-
quently used measures of QoL, MIDs have been estab-
lished for the TOIs for several FACIT instruments. Table 1
provides a list of established MIDs:
These MIDs can be used to aid the interpretation of group
differences and changes in HRQOL over time, and they
can be useful in sample size calculations.
Has the FACIT been used in individual patient assessment?
Yes. The FACT-G has been used extensively in clinic-based
evaluations of individual patients. Instruments like the
FACT-G, relatively brief, multidimensional question-
naires, are designed primarily for group comparisons,
lacking precision needed for individual diagnosis. Never-
theless, individual assessment using the FACT-G has been
helpful to patients and clinicians attempting to estimate
change over time. It can also be a useful "springboard" for
discussion. We have developed more accurate assessment
from our item response theory (IRT)-derived item-banks
that are indeed sufficiently precise for individual diagno-
sis. Each of our IRT-derived item banks (pain, fatigue,
physical function, emotional distress, etc.) can be admin-
istered to patients using a computerized assessment algo-
rithm, which selects only those questions that will add to
the precision of the measurement estimate. This proce-
dure, called computerized adaptive testing (CAT), results
in brief, accurate assessment of the selected HRQOL
domains.
Is there Item Banking of the FACIT Questionnaires?
Yes. Our item-banking program is very active. There are
two types of item banks. The first is a simple compilation
of all items (questions) available in our database. We have
over 400 questions in this "general" item bank, and most
of them have been translated into several languages.
A second kind of item bank is one that can be created from
large sample datasets using IRT modeling techniques. We
have this item bank as well. Our current item banks
include the following HRQOL domains: fatigue (72
items); pain (43 items); physical functioning (43 items);
general emotional distress (48 items); cognitive com-
plaints (35 items); and illness-specific concerns (46
items). We have several other IRT-derived item banks in
development.
In which populations has the FACIT been used?
The FACIT Measurement System has questionnaires tar-
geted to:
• Cancer
• HIV Disease
• Multiple Sclerosis
• Arthritis
• Parkinson's Disease
Table 1: Minimally important differences for select FACIT scales
Instrument Scale/Subscale MID (points) Reference
FACT-G PWB 2–3 [28]
SWB NA
EWB 2* [28,29]
FWB 2–3 [28]
Total FACT-G 3–7 [27,28,30,31]
FACT-Anemia Fatigue Subscale 3–4 [27,31]
TOI-Fatigue 5 [27]
TOI-Anemia 6
Total FACT-Anemia 7
FACT-Breast Breast cancer subscale 2–3 [30]
TOI-Breast 5–6
Total FACT-Breast 7–8
FACT-Colorectal Colorectal cancer subscale 2–3 [32]
TOI-Colorectal 4–6
Total FACT-Colorectal 5–8
FACT-Head & Neck Total FACT-Head & Neck 6–12 [33]
FACT-Lung Lung cancer subscale 2–3 [34]
TOI-Lung 5–6
*This MID should be considered tentative as it may be revised based on future research.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/79
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• Stroke
• Other non-life-threatening chronic illnesses or
conditions
• General medical practice
How may we obtain a copy of the questionnaires, 
permission for use, or more information about the FACIT 
Measurement System?
You may obtain user-ready copies of all available English
language FACIT measures, permission for use of a FACIT
measure, and a variety of other information regarding the
FACIT Measurement System on our website at http://
www.facit.org.
How much does it cost to purchase the FACIT itself?
License for use of any English version of a FACIT measure
is granted free of charge. Collaborators are asked to agree
to a simple user agreement and to register their use of a
FACIT questionnaire by completing a Collaborators'
Project Information Form. License for use of a translated
questionnaire may require a fee. This decision is made on
an individual project basis according to the nature of the
trial, the questionnaires and translations to be used, the
sponsor, and existing contractual arrangements.
How can we obtain scientific support during our study?
Consultation services are available. Please contact http://
information@facit.org with a description of your research
project or clinical trial and support needs.
Conclusion
The Functional Assessment of Chronic Illness Therapy
(FACIT) Measurement System is a collection of health-
related quality of life (HRQOL) questionnaires that assess
multidimensional health status in people with various
chronic illnesses, including cancer. The measurement sys-
tem, under development since 1987, began with the crea-
tion of a generic CORE questionnaire called the
Functional Assessment of Cancer Therapy-General (FACT-
G). The FACT-G (now in Version 4) is a 27-item compila-
tion of general questions divided into four primary QOL
domains: Physical Well-Being, Social/Family Well-Being,
Emotional Well-Being, and Functional Well-Being. It is
appropriate for use with patients with any form of cancer,
and extensions of it have been used and validated in other
chronic illness condition (e.g., HIV/AIDS; multiple sclero-
sis; Parkinson's disease; rheumatoid arthritis), and in the
general population. The FACIT Measurement System now
includes over 400 questions, some of which have been
translated into more than 45 languages. Assessment of
any one patient is tailored so that the most-relevant ques-
tions are asked and administration time for any one
assessment is usually less than 15 minutes. This is accom-
plished both by the use of specific subscales for relevant
domains of HRQOL, or computerized adaptive testing
(CAT) of selected symptoms and functional areas. FACIT
questionnaires can be administered by self-report (paper
or computer) or interview (face-to-face or telephone).
Available scoring, normative data and information on
meaningful change now allow one to interpret results in
the context of a growing literature base.
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